Skip to main content

Table 1 Baseline characteristics, length of stay and outcome of the study patients

From: Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study

 

TP (n = 15)

AVP (n = 15)

NE (n = 15)

P value

Age, years

67 (60; 71)

66 (60; 74)

64 (59; 72)

0.889

Gender, male

73%

67%

80%

0.717

Body weight, kg

85 (79; 100)

85 (71; 98)

85 (78; 90)

0.612

SAPS II

62 (57; 72)

60 (49; 66)

58 (52; 68)

0.664

Cause of septic shock

Necrotizing fasciitis (n = 1)

Endocarditis (n = 1)

Pancreatitis (n = 4)

0.438

 

Pancreatitis (n = 3)

Necrotizing fasciitis (n = 2)

Peritonitis (n = 6)

 
 

Peritonitis (n = 5)

Peritonitis (n = 6)

Pneumonia (n = 5)

 
 

Pneumonia (n = 6)

Pneumonia (n = 6)

  

ICU mortality

7/15

8/15

10/15

0.533

ICU length of stay

14 (9; 25)

17 (5; 27)

17(7; 23)

0.878

  1. Data are given as median (25%; 75% range).
  2. AVP = arginine vasopressin; ICU = intensive care unit; NE = norepinephrine; TP = terlipressin; SAPS II = simplified acute physiology score II.